Login to Your Account



Knowing When to Fold 'Em: Amicus Pompe Phase II Solid

By Randy Osborne
Staff Writer

Friday, October 12, 2012
Positive preliminary data from a Phase II trial with Amicus Therapeutics Inc.'s drug chaperone in Pompe disease, unveiled at an Australian scientific meeting, tickled the company's share price, but investors must wait until year's end for the complete results.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription